Ep205: Heather Turner on a Schizophrenia Drug Patients Can Stick With
About this episode
Heather Turner discusses the development of a new schizophrenia drug aimed at improving patient adherence.
Heather Turner, CEO of New York-based LB Pharma, on developing a new schizophrenia drug designed to better cross the blood-brain barrier, be dosed once daily, and make it easier for patients to take long term.
More episodes of The Long Run with Luke Timmerman
- Ep204: Troy Wilson on Precision Cancer Drugs and Combos
- Ep203: Sri Kosuri on Small Molecule Correctors of Disease
Explore listener stats, chart rankings, contacts and more on the The Long Run with Luke Timmerman podcast page.